Previous research has found that the loss of IFNG reduces the therapeutic effects against AML (Matte-Martone et al., 2017), that IFNG mitigates resistance to anticancer drugs in BC (Showalter et al., 2019), that it is a key factor in the treatment of RA (He et al., 2020) and that it is poorly expressed in T1DM (Sasaki et al., 2004; Vaseghi et al., 2016); thus, it is possible that the activation of IFNG would have therapeutic effects in these diseases. This evidence concerns the gene IFNG and breast cancer.